About Corvus Pharmaceuticals (NASDAQ:CRVS)
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Biotechnology & Medical Research - NEC
- Symbol: NASDAQ:CRVS
- CUSIP: N/A
- Web: www.corvuspharma.com
- Current Ratio: 10.12%
- Quick Ratio: 10.12%
Sales & Book Value:
- Annual Sales: N/A
- Price / Sales: N/A
- Book Value: $4.45 per share
- Price / Book: 2.53
- Trailing EPS: ($2.69)
- Net Income: ($36,370,000.00)
- Return on Equity: -48.78%
- Return on Assets: -44.98%
- Employees: 44
- Outstanding Shares: 21,040,000
Frequently Asked Questions for Corvus Pharmaceuticals (NASDAQ:CRVS)
What is Corvus Pharmaceuticals' stock symbol?
Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."
How were Corvus Pharmaceuticals' earnings last quarter?
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its earnings results on Thursday, November, 2nd. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.19. View Corvus Pharmaceuticals' Earnings History.
Where is Corvus Pharmaceuticals' stock going? Where will Corvus Pharmaceuticals' stock price be in 2017?
4 equities research analysts have issued twelve-month price objectives for Corvus Pharmaceuticals' stock. Their predictions range from $14.00 to $26.00. On average, they expect Corvus Pharmaceuticals' share price to reach $21.67 in the next year. View Analyst Ratings for Corvus Pharmaceuticals.
What are Wall Street analysts saying about Corvus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Corvus Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. " (11/7/2017)
- 2. Cowen and Company analysts commented, "CRVS has expanded its clinical trial collab with Genentech to include a Phase Ib/II trial." (5/2/2017)
Are investors shorting Corvus Pharmaceuticals?
Corvus Pharmaceuticals saw a increase in short interest during the month of October. As of October 13th, there was short interest totalling 1,293,252 shares, an increase of 39.6% from the September 29th total of 926,344 shares. Based on an average daily trading volume, of 75,031 shares, the days-to-cover ratio is presently 17.2 days. Approximately 9.5% of the shares of the stock are sold short.
Who are some of Corvus Pharmaceuticals' key competitors?
Some companies that are related to Corvus Pharmaceuticals include Concert Pharmaceuticals (CNCE), Celyad SA (CYAD), Mesoblast Limited (MESO), Kala Pharmaceuticals (KALA), PDL BioPharma (PDLI), Inovio Pharmaceuticals (INO), Cara Therapeutics (CARA), Celldex Therapeutics (CLDX), Idera Pharmaceuticals (IDRA), Novavax (NVAX), Protalix Biotherapeutics (PLX), Horizon Discovery Group PLC (HZD), Voyager Therapeutics (VYGR), NewLink Genetics Corporation (NLNK), Protagonist Therapeutics (PTGX), ChromaDex Corporation (CDXC), Agenus (AGEN) and Arbutus Biopharma Corporation (ABUS).
Who are Corvus Pharmaceuticals' key executives?
Corvus Pharmaceuticals' management team includes the folowing people:
- Richard A. Miller M.D., Chairman of the Board, President, Chief Executive Officer (Age 66)
- Leiv Lea, Chief Financial Officer (Age 63)
- Jason V. Coloma Ph.D., Senior Vice President and Chief Business Officer (Age 41)
- William Benton Jones Ph.D., Vice President of Pharmaceutical Development (Age 52)
- Erik J. Verner Ph.D., Vice President of Chemistry Research (Age 52)
- Ian T. Clark, Independent Director (Age 56)
- Elisha P. Gould III, Independent Director (Age 60)
- Steve E. Krognes, Independent Director (Age 48)
- Peter Moldt Ph.D., Independent Director (Age 58)
- Scott W. Morrison, Independent Director (Age 59)
When did Corvus Pharmaceuticals IPO?
(CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
Who owns Corvus Pharmaceuticals stock?
Corvus Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Jennison Associates LLC (4.24%), JPMorgan Chase & Co. (1.50%), Sphera Funds Management LTD. (1.05%), Point72 Asset Management L.P. (0.93%) and Dimensional Fund Advisors LP (0.10%). Company insiders that own Corvus Pharmaceuticals stock include A/S Novo, Adams Street Partners Llc, Holdings A/S Novo, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller. View Institutional Ownership Trends for Corvus Pharmaceuticals.
Who sold Corvus Pharmaceuticals stock? Who is selling Corvus Pharmaceuticals stock?
Corvus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Point72 Asset Management L.P., Sphera Funds Management LTD., JPMorgan Chase & Co. and Dimensional Fund Advisors LP. View Insider Buying and Selling for Corvus Pharmaceuticals.
How do I buy Corvus Pharmaceuticals stock?
Shares of Corvus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corvus Pharmaceuticals' stock price today?
One share of Corvus Pharmaceuticals stock can currently be purchased for approximately $11.27.
How big of a company is Corvus Pharmaceuticals?
Corvus Pharmaceuticals has a market capitalization of $242.18 million. The company earns ($36,370,000.00) in net income (profit) each year or ($2.69) on an earnings per share basis. Corvus Pharmaceuticals employs 44 workers across the globe.
How can I contact Corvus Pharmaceuticals?
MarketBeat Community Rating for Corvus Pharmaceuticals (NASDAQ CRVS)MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Corvus Pharmaceuticals' mailing address is 863 Mitten Rd Ste 102, BURLINGAME, CA 94010-1311, United States. The company can be reached via phone at +1-650-9004520 or via email at [email protected]
Analysts' Consensus Ratings for Corvus Pharmaceuticals (NASDAQ:CRVS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 3 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.75)|
|Consensus Price Target: ||$21.67 (92.25% upside)|Consensus Price Target History for Corvus Pharmaceuticals (NASDAQ:CRVS)
Analysts' Ratings History for Corvus Pharmaceuticals (NASDAQ:CRVS)
(Data available from 11/17/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/23/2017||Credit Suisse Group||Upgrade||Underperform -> Neutral||$14.00||High|
|7/4/2017||Cowen and Company||Reiterated Rating||Outperform||Medium|
|4/5/2017||Cantor Fitzgerald||Reiterated Rating||Buy||$25.00||High|
|6/2/2016||BTIG Research||Initiated Coverage||Buy||N/A|
Earnings History for Corvus Pharmaceuticals (NASDAQ:CRVS)Earnings History by Quarter for Corvus Pharmaceuticals (NASDAQ CRVS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Corvus Pharmaceuticals (NASDAQ:CRVS)
2017 EPS Consensus Estimate: ($2.27)
2018 EPS Consensus Estimate: ($3.51)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Corvus Pharmaceuticals (NASDAQ:CRVS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Corvus Pharmaceuticals (NASDAQ CRVS)
Institutional Ownership Percentage: 82.57%Insider Trades by Quarter for Corvus Pharmaceuticals (NASDAQ CRVS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/23/2017||Holdings A/S Novo||Major Shareholder||Buy||20,000||$10.95||$219,000.00|| |
|6/13/2017||Richard A Md Miller||Insider||Buy||25,000||$9.88||$247,000.00|| |
|6/24/2016||Orbimed Advisors Llc||Director||Buy||1,000||$12.98||$12,980.00|| |
|6/21/2016||Orbimed Advisors Llc||Director||Buy||38,383||$12.75||$489,383.25|| |
|6/16/2016||Orbimed Advisors Llc||Director||Buy||20,000||$12.35||$247,000.00|| |
|6/10/2016||Peter A Thompson||Director||Buy||50,000||$12.96||$648,000.00|| |
|5/20/2016||Orbimed Advisors Llc||Director||Buy||4,716||$13.09||$61,732.44|| |
|5/19/2016||Peter A Thompson||Director||Buy||6,800||$11.77||$80,036.00|| |
|5/13/2016||Richard A Md Miller||CEO||Buy||30,300||$10.00||$303,000.00|| |
|5/12/2016||A/S Novo||Major Shareholder||Buy||70,000||$10.00||$700,000.00|| |
|3/29/2016||Adams Street Partners Llc||Major Shareholder||Buy||200,000||$15.00||$3,000,000.00|| |
|3/29/2016||Peter A Thompson||Director||Buy||550,000||$15.00||$8,250,000.00|| |
Headline Trends for Corvus Pharmaceuticals (NASDAQ:CRVS)
Latest Headlines for Corvus Pharmaceuticals (NASDAQ CRVS)
|Corvus Pharmaceuticals Is Now Oversold (CRVS)|
www.thestreet.com - November 14 at 10:59 PM
|Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection|
finance.yahoo.com - November 11 at 10:36 PM
|FY2017 EPS Estimates for Corvus Pharmaceuticals, Inc. (CRVS) Increased by Analyst|
www.americanbankingnews.com - November 8 at 9:51 AM
|Corvus Pharmaceuticals, Inc. (CRVS) Upgraded to Buy at Zacks Investment Research|
www.americanbankingnews.com - November 7 at 8:26 PM
|Corvus Pharmaceuticals, Inc. (CRVS) Posts Earnings Results, Beats Expectations By $0.19 EPS|
www.americanbankingnews.com - November 3 at 5:48 PM
|Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results And Clinical Program Update|
www.thestreet.com - November 2 at 6:30 PM
|Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update|
finance.yahoo.com - November 2 at 6:30 PM
|Corvus Pharmaceuticals, Inc. (CRVS) Short Interest Update|
www.americanbankingnews.com - October 28 at 1:26 AM
|Oversold Conditions For Corvus Pharmaceuticals (CRVS)|
www.thestreet.com - October 26 at 2:44 PM
|Corvus Pharmaceuticals to Present Data on Lead Checkpoint Inhibitor CPI-444 at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting|
finance.yahoo.com - October 18 at 6:54 PM
|Comparing Ionis Pharmaceuticals (IONS) & Corvus Pharmaceuticals (CRVS)|
www.americanbankingnews.com - October 17 at 4:30 PM
|Corvus Pharmaceuticals, Inc. (CRVS) Upgraded to Hold at Zacks Investment Research|
www.americanbankingnews.com - October 11 at 12:04 AM
|Corvus Pharmaceuticals to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference|
finance.yahoo.com - September 20 at 6:20 PM
|Contrasting Corvus Pharmaceuticals (CRVS) and The Competition|
www.americanbankingnews.com - September 14 at 12:26 AM
|Corvus Pharmaceuticals, Inc. (CRVS) Expected to Announce Earnings of -$0.85 Per Share|
www.americanbankingnews.com - September 3 at 10:24 PM
|UPDATE: Credit Suisse Upgrades Corvus Pharmaceuticals (CRVS) to Neutral|
www.streetinsider.com - August 24 at 5:43 PM
|Corvus Pharmaceuticals, Inc. (CRVS) Upgraded to Neutral at Credit Suisse Group|
www.americanbankingnews.com - August 23 at 9:42 PM
| Brokerages Expect Corvus Pharmaceuticals, Inc. (CRVS) Will Announce Earnings of -$0.85 Per Share|
www.americanbankingnews.com - August 16 at 10:16 AM
|Corvus Pharmaceuticals to Present at the 2017 Wedbush PacGrow Healthcare Conference|
feeds.benzinga.com - August 11 at 8:59 PM
|FY2017 Earnings Estimate for Corvus Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (NASDAQ:CRVS)|
www.americanbankingnews.com - August 10 at 1:16 PM
|Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives "Outperform" Rating from Wedbush|
www.americanbankingnews.com - August 8 at 8:56 PM
|Research Analysts Set Expectations for Corvus Pharmaceuticals, Inc.'s Q2 2017 Earnings (NASDAQ:CRVS)|
www.americanbankingnews.com - August 7 at 7:04 AM
|Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Issues Earnings Results, Beats Estimates By $0.03 EPS|
www.americanbankingnews.com - August 5 at 2:34 PM
|Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update|
finance.yahoo.com - August 3 at 6:59 PM
|Corvus Pharmaceuticals, Inc. (CRVS) Coverage Initiated at Wedbush|
www.americanbankingnews.com - August 2 at 5:48 PM
|Contrasting Jaguar Animal Health (JAGX) and Corvus Pharmaceuticals (CRVS)|
www.americanbankingnews.com - August 2 at 7:58 AM
|Analyzing Corvus Pharmaceuticals (CRVS) and OncoGenex Pharmaceuticals (OGXI)|
www.americanbankingnews.com - July 20 at 2:32 PM
|Corvus Pharmaceuticals, Inc. (CRVS) to Post FY2017 Earnings of ($2.60) Per Share, Cantor Fitzgerald Forecasts|
www.americanbankingnews.com - July 17 at 10:14 AM
|Corvus Pharmaceuticals to Host R&D Day Highlighting Role of Adenosine Pathway in Immuno-Oncology|
finance.yahoo.com - July 6 at 6:48 PM
|Corvus Pharmaceuticals and Monash University Enter into Exclusive License Agreement for Novel Immuno-Oncology Program|
globenewswire.com - May 9 at 4:30 PM
|Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update|
us.rd.yahoo.com - March 10 at 5:35 PM
|CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition|
us.rd.yahoo.com - March 10 at 5:35 PM
|Corvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-444|
us.rd.yahoo.com - January 10 at 5:18 PM
|CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events|
us.rd.yahoo.com - January 10 at 5:18 PM
|4:11 pm Corvus Pharmaceuticals names Ian T. Clark to Board of Directors; Clark was the former CEO of Genetech|
us.rd.yahoo.com - January 4 at 3:31 AM
|CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure|
us.rd.yahoo.com - January 4 at 3:31 AM
|Corvus Pharma (CRVS) Appoints Ian Clark to Board of Directors|
www.streetinsider.com - January 3 at 10:30 PM
|ContraVir Pharma (CTRV) Announces Positive Update on CRV431 as HBV Treatment|
www.streetinsider.com - December 8 at 7:37 AM
|ContraVir's Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis B|
www.prnewswire.com - December 8 at 7:37 AM
|CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers|
biz.yahoo.com - December 8 at 7:37 AM
|Corvus Pharma (CRVS) Offers Encouraging Data from CPI-444 Combo Biomarker Phase 1/1b|
www.streetinsider.com - October 12 at 9:10 AM
|Corvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at Second CRI-CIMT|
www.nasdaq.com - September 19 at 9:04 AM
|Gilead Has a Problem. These Three Biotechs Could Be the Solution|
blogs.barrons.com - July 22 at 2:08 PM
|CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements|
biz.yahoo.com - May 5 at 4:44 PM
|CORVUS PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report|
biz.yahoo.com - May 5 at 4:36 PM
|CORVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits|
biz.yahoo.com - April 20 at 6:04 AM
|U.S. IPO Market In Desperate Need Of Some Oxygen After Q1|
seekingalpha.com - April 12 at 3:27 PM
|Corvus Pharmaceuticals To Present At AACR Annual Meeting April 16 - 20 In New Orleans|
www.thestreet.com - April 5 at 3:13 PM
|[$$] IPOs: The Worst Yearly Start Since the Recession|
www.barrons.com - April 2 at 12:01 AM
|[$$] IPO Market Flashes Red for Stocks|
www.wsj.com - April 1 at 10:24 AM
Corvus Pharmaceuticals (NASDAQ CRVS) Chart for Friday, November, 17, 2017